Incannex Healthcare Inc. stock fell nearly 20% in premarket after the company priced a $10 million private placement at $5 per share, below its previous close. The proceeds will fund its sleep apnea drug program, but investors reacted negatively, as Phase 3 trials are not expected to begin until the second half of 2027.
Sponsored Advertisement
No comments yet. Be the first!